Aβ binding molecules
US7575747B2 · kind B2 · utility
8Cited by
14References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2004 |
| Grant date | Aug 18, 2009 |
| Priority date | — |
| Expiry date | Jan 16, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.